511 related articles for article (PubMed ID: 22213298)
21. Studies on activities, cell uptake and DNA binding of four trans-planaramineplatinum(II) complexes of the form: trans-PtL(NH3)Cl2, where L=2-hydroxypyridine, imidazole, 3-hydroxypyridine and imidazo(1,2-alpha)pyridine.
Huq F; Yu JQ; Daghriri H; Beale P
J Inorg Biochem; 2004 Aug; 98(8):1261-70. PubMed ID: 15271501
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and cytotoxicity of three trans-palladium complexes containing planaramine ligands in human ovarian tumor models.
Mazumder ME; Beale P; Chan C; Yu JQ; Huq F
ChemMedChem; 2012 Oct; 7(10):1840-6. PubMed ID: 22899663
[TBL] [Abstract][Full Text] [Related]
23. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
24. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
25. Studies of interaction of trichloro{eta2-cis-N,N-dimethyl-1-[6-(N',N'-dimethyl-ammoniummethyl)-cyclohex-3-ene-1-yl]-methylammonium}platinum(II) chloride with DNA: Effects on secondary and tertiary structures of DNA. Cytotoxic assays on human ovarian cancer cell lines, resistant and non-resistant to cisplatin.
Gay M; Montaña AM; Moreno V; Prieto MJ; Pérez JM; Alonso C
Bioorg Med Chem; 2006 Mar; 14(5):1565-72. PubMed ID: 16256352
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and activity of three new trinuclear platinums with cis-geometry for terminal metal centres.
Hamad SA; Beale P; Yu JQ; Huq F
J Biomed Sci; 2014 May; 21(1):41. PubMed ID: 24884683
[TBL] [Abstract][Full Text] [Related]
27. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
28. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and activity of [{Cis-PtCl(NH3)2}2µ{trans-Pt(3-Hydroxypyridine)2(H2N(CH2)6NH2)2}]Cl4 in the human ovarian tumour models.
Hamad SA; Beale P; Yu JQ; Fisher K; Huq F
Med Chem; 2012 May; 8(3):384-91. PubMed ID: 22530892
[TBL] [Abstract][Full Text] [Related]
30. Studies on activities, cell up take and DNA binding of four multinuclear complexes of the form: [[trans-PtCl(NH(3))(2)](2)mu-[trans-Pd(NH(3))(2)-(H(2)N(CH(2))(n)NH(2))(2)]]Cl(4) where n=4-7.
Daghriri H; Huq F; Beale P
J Inorg Biochem; 2004 Nov; 98(11):1722-33. PubMed ID: 15522400
[TBL] [Abstract][Full Text] [Related]
31. Changes in the in vitro activity of platinum drugs when administered in two aliquots.
Al-Eisawi Z; Beale P; Chan C; Yu JQ; Proschogo N; Molloy M; Huq F
BMC Cancer; 2016 Aug; 16(1):688. PubMed ID: 27566066
[TBL] [Abstract][Full Text] [Related]
32. A hybrid platinum drug dichloroacetate-platinum(II) overcomes cisplatin drug resistance through dual organelle targeting.
Zhang Y; Guo G; Ma B; Du R; Xiao H; Yang X; Li W; Gao Y; Li Y; Jing X
Anticancer Drugs; 2015 Aug; 26(7):698-705. PubMed ID: 25811961
[TBL] [Abstract][Full Text] [Related]
33. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
[TBL] [Abstract][Full Text] [Related]
34. Studies on combination of platinum drugs cisplatin and oxaliplatin with phytochemicals anethole and curcumin in ovarian tumour models.
Nessa MU; Beale P; Chan C; Yu JQ; Huq F
Anticancer Res; 2012 Nov; 32(11):4843-50. PubMed ID: 23155250
[TBL] [Abstract][Full Text] [Related]
35. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
Behrens BC; Hamilton TC; Masuda H; Grotzinger KR; Whang-Peng J; Louie KG; Knutsen T; McKoy WM; Young RC; Ozols RF
Cancer Res; 1987 Jan; 47(2):414-8. PubMed ID: 3539322
[TBL] [Abstract][Full Text] [Related]
36. Enhanced Accumulation of Cisplatin in Ovarian Cancer Cells from Combination with Wedelolactone and Resulting Inhibition of Multiple Epigenetic Drivers.
Sarwar S; Alamro AA; Alghamdi AA; Naeem K; Ullah S; Arif M; Yu JQ; Huq F
Drug Des Devel Ther; 2021; 15():2211-2227. PubMed ID: 34079223
[TBL] [Abstract][Full Text] [Related]
37. Anti-proliferative and pro-apoptotic effects from sequenced combinations of andrographolide and cisplatin on ovarian cancer cell lines.
Yunos NM; Mutalip SS; Jauri MH; Yu JQ; Huq F
Anticancer Res; 2013 Oct; 33(10):4365-71. PubMed ID: 24123004
[TBL] [Abstract][Full Text] [Related]
38. Studies on the synthesis and activity of three tripalladium complexes containing planaramine ligands.
Farhad M; Yu JQ; Beale P; Fisher K; Huq F
ChemMedChem; 2009 Nov; 4(11):1841-9. PubMed ID: 19746359
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and characterization of palladium(II) and platinum(II) complexes with Schiff bases derivatives of 2-pyridincarboxyaldehyde. Study of their interaction with DNA.
García-Friaza G; Fernández-Botello A; Pérez JM; Prieto MJ; Moreno V
J Inorg Biochem; 2006 Aug; 100(8):1368-77. PubMed ID: 16712937
[TBL] [Abstract][Full Text] [Related]
40. Combinations of platinums and selected phytochemicals as a means of overcoming resistance in ovarian cancer.
Huq F; Yu JQ; Beale P; Chan C; Arzuman L; Nessa MU; Mazumder ME
Anticancer Res; 2014 Jan; 34(1):541-5. PubMed ID: 24403514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
